| 摘要 |
The disclosure includes protocols for activating and administering human blood cells to severely myelosuppressed patients, including patients treated for cancer, e.g., by chemotherapy or radiation. The protocol may include culturing blood cells in the presence of activating agents, for example, a cytokine and an ionophore.
|
